Dry Eye in Sjögren's Syndrome When Initial Therapy Falls Short
Sjögren's syndrome is a systemic autoimmune inflammatory disease that causes dry eye and dry mouth. When the first line of management does not bring adequate improvement in dry eye symptoms, a structured next-step approach is indicated.
Clinical Scenario
Sjögren's syndrome with persistent dry eye and dry mouth — symptoms that have not resolved sufficiently despite the initial course of conservative management.
When This Protocol Applies — Previous Treatment Fell Short
First-line management for Sjögren's-related dry eye — environmental modifications and omega-3 fatty acid supplementation — targets an increase in tear secretion and a decrease in tear evaporation within one month. This protocol is the defined next step when those goals are not met.
Next-Line Treatment Approach (Overview)
At this stage, artificial tear substitutes are the cornerstone of management. The appropriate formulation depends on how long ocular retention is required — options span from standard tear solutions to preparations designed for extended contact time. The full selection criteria, sequencing, and clinical decision points are set out in the complete protocol.
Treatment Goals
Stabilisation of the tear film, prolonged tear break-up time, and decreased tear osmolarity.
References
Sjogren's syndrome is a systemic autoimmune inflammatory disease that causes dry eye and dry mouth.
When clinical symptoms and signs persist, most patients are advised to use tear substitutes.
Artificial tear substitutes are the most often used treatment for DED, regardless of the severity of the disease.
Most patients use tear solutions, but products with a longer ocular-retention time, a gel, ointment, or the ophthalmic hydroxypropyl cellulose insert (Lacrisert), may be used if needed.
It has been shown to be clinically beneficial in that it stabilizes the tear film, prolongs tear break-up time, and lubricates the eye.
View source ↗